Our mission

Ensure every patient can participate in clinical trials for the most promising treatments

This is how your doctor's visit should actually work, with a global, open treatment evidence network.

  • Treatment rankings based on real-world outcomes
  • An Outcome Label for every treatment
  • Patient data that stays with patients and their clinics

Every patient helps the next

  1. 1

    Compare

    You and your doctor see which treatments worked for people like you.

  2. 2

    Join

    You start one as part of your normal care, in a pragmatic trial.

  3. 3

    Report

    You record how you feel, and your health records add the rest.

  4. 4

    Improve

    Your results update the rankings and Outcome Labels for the next patient.

Then the next patient starts at step 1, with better evidence.

Care-integrated clinical trials, explained in two minutes

Comparative Effectiveness Rankings

Patients and doctors would see which treatments worked best for people with the same condition

Interventions by Condition
Rankings would update as patients report outcomes. The scores shown are the prototype's AI-assisted estimates.
  1. Rank 1

    Electroconvulsive Therapy (ECT)

    90/ 100

    Effectiveness estimate

    Safety estimate: 40 / 100

  2. Rank 2

    Venlafaxine (SNRI)

    80/ 100

    Effectiveness estimate

    Safety estimate: 60 / 100

  3. Rank 3

    Cognitive Behavioral Therapy (CBT)

    78/ 100

    Effectiveness estimate

    Safety estimate: 95 / 100

  4. Rank 4

    Sertraline (SSRI)

    76/ 100

    Effectiveness estimate

    Safety estimate: 60 / 100

  5. Rank 5

    Mirtazapine

    75/ 100

    Effectiveness estimate

    Safety estimate: 60 / 100

Top 5 of 6 treatments. Scores use a 0–100 scale, not response percentages.

Outcome Labels

Every treatment would have a label showing how much it helps and how often it harms, compared with placebo, usual care or other treatments

  • How much it helps, on the scales doctors use
  • How often each side effect happens, next to the comparison group
  • Where every number comes from
LecanemabAlzheimer's disease

Changes are compared with placebo in lecanemab's trials.

Primary outcome estimates

Bars show points of decline by the end of the trial. Shorter is better.

Dementia severity (CDR-SB)Baseline: 3.17 points (CDR-SB 0-18 scale)
27% less decline than placebo (-0.45 points)
Lecanemab1.21 points
Placebo1.66 points
Thinking and memory (ADAS-Cog14)Baseline: 24.45 points (ADAS-Cog14 0-90 scale)
26% less decline than placebo (-1.44 points)
Lecanemab4.14 points
Placebo5.58 points
Daily activities (ADCS-MCI-ADL)Baseline: 41.2 points (ADCS-MCI-ADL 0-53 scale)
37% less decline than placebo (+2.0 points)
Lecanemab3.5 points
Placebo5.5 points
Brain Amyloid Plaque (PET Centiloids)Baseline: Not providedSource: Published study (opens in a new tab)
-59.1 Centiloids compared with placebo
Other outcome estimates
Plasma Aβ42/40 ratioBaseline: 0.088
+0.007 compared with placebo
Plasma p-tau181Baseline: 3.70 pg/mL
-0.78 pg/mL compared with placebo
Side-effect estimates

Share of patients who had each one.

Infusion reactions
Lecanemab26%
Placebo7%
Brain swelling (ARIA-E)
Lecanemab13%
Placebo2%
Signs of brain bleeding (ARIA-H)
Lecanemab17%
Placebo9%
Headache
Lecanemab11%
Placebo8%

Source: FDA label (opens in a new tab), unless noted

Every patient on Earth helps the next one

Today, results stay inside the hospital, company or country that collected them, and most treated patients add nothing to what doctors know. In one open network, a patient in Nairobi who reports how a treatment worked improves the outcome label a doctor reads in Seoul.

  • Any clinic, in any country, reports outcomes in one open format.
  • De-identified results are pooled in one public database. The records stay with patients and their clinics.
  • Rankings and outcome labels update as results arrive, for every patient, everywhere.

Every disease gets studied in every country at once, and nobody waits for someone else's trial.

How Medicine Should Actually Work

Patients would report outcomes, doctors would see what has worked for patients like theirs, and researchers would run trials on the same network.

For patients

How Your Doctor's Visit Should Actually Work

Compare the Most Promising Treatments for Your Condition

See the treatments for your condition ranked side by side, each with an outcome label.

  • Compare effectiveness, side effects and cost side by side
  • See how strong the evidence is for each treatment
  • Find participating clinics near you
  • Talk the options over with your own doctor
Alzheimer's disease
Comparative Effectiveness Rankings (estimated, out of 100)
Donanemab
FDA approved
57/100
Lecanemab
FDA approved
55/100
Donepezil
FDA approved
45/100
Rivastigmine
FDA approved
43/100
Galantamine
FDA approved
42/100
Memantine
FDA approved
40/100

View Outcome Labels

Review what is known about a treatment before deciding, with the source of every number.

  • See results from trials and from treated patients
  • Understand potential side effects and their frequency
  • Compare with standard of care treatments
  • Check the source of every value
LecanemabAlzheimer's disease
Primary outcome estimates

Bars show points of decline by the end of the trial. Shorter is better.

Dementia severity (CDR-SB)Baseline: 3.17 points (CDR-SB 0-18 scale)
27% less decline than placebo (-0.45 points)
Lecanemab1.21 points
Placebo1.66 points
Thinking and memory (ADAS-Cog14)Baseline: 24.45 points (ADAS-Cog14 0-90 scale)
26% less decline than placebo (-1.44 points)
Lecanemab4.14 points
Placebo5.58 points
Side-effect estimates

Share of patients who had each one.

Infusion reactions
Lecanemab26%
Placebo7%
Brain swelling (ARIA-E)
Lecanemab13%
Placebo2%
Signs of brain bleeding (ARIA-H)
Lecanemab17%
Placebo9%

Source: FDA label (opens in a new tab)

Decide in Writing

Sign a plain-language consent with your doctor: the treatment, the risks, the unknowns and the cost.

  • Sign online, after talking it over with your doctor
  • Known and unknown risks in plain language
  • The cost, and who pays, before you start
  • Stop at any time
Informed Consent
I understand this treatment's known and unknown risks, and that my outcome will be recorded.
I have reviewed the outcome label
I know the other options, including none
I know the cost and who pays
Sign consent

Coordinate Your Care

Book the trial's lab tests and visits at the clinic you already use.

  • Labs and visits at your usual clinic
  • Video check-ins instead of trips to a trial site
  • Your records come in, so you don't repeat your history
  • A reminder before each appointment
Your Care Schedule
Cognitive Assessment
Neurology Center
May 15
9:30 AM
Virtual Check-in
Dr. Robert Chen, Neurologist
May 22
2:00 PM
Join Now
Import Health Records
Schedule New Appointment

Track Outcomes

Quick check-ins record how you're doing. Every result, good or bad, improves the outcome labels for the next patient.

  • A short check-in by app, text or phone
  • Wearables can add sleep and activity
  • Only the measures your trial needs
  • Your data stays with you and your clinic
Daily Tracking
Week 6 · Today
Memory test
28 / 30
Steady over 6 weeks
Doses
Morning doseTaken 8:02 AM
Evening doseDue 8:00 PM
Check-in
Answered by phone, no side effects
Next check-in tomorrow at 9:00 AM

See Whether It's Working

Your check-ins are charted over time next to patients on the same treatment, so you and your doctor can decide whether to continue, change the dose or stop.

  • Your scores over time, from your check-ins
  • Next to patients on the same treatment
  • Your doctor sees the same chart
  • Problems you report are flagged for your next visit
Your Treatment Response
Memory test score
Stable
Month 1Month 6
Next to others on this treatment
Your score is in the middle of the range for patients six months into this treatment.
For your doctor
You have reported daytime fatigue on most days since starting treatment. We flagged it for your next visit.

Check In by Phone or Text

A short daily call or text asks how you feel and records your answer, so you don't fill in forms.

  • Answer in your own words
  • Side effects you mention go to your doctor
  • A reminder when a dose is due
  • Ask how your check-ins compare with others on the same treatment

Daily check-in

By phone or text

Good morning, Sarah! How are you feeling today after your treatment yesterday?

I'm feeling better today. The headache is gone but I still feel a bit tired.

Thanks, Sarah. I've recorded that, and I'll let your doctor know you still feel tired. Would you like to see how your check-ins compare with other patients on the same treatment?

Yes, please show me.

Your answers go into your record, and your doctor sees any side effects you mention

For doctors

How Treating Patients Should Work

Review Screened Options for Your Patient

See the treatments an independent board has screened for your patient's condition, ranked by the evidence so far. The ranking supports your judgment; it does not replace it.

  • Options ranked by outcomes from trials and treated patients
  • Eligibility checked against your patient's record
  • An outcome label, with sources, for every option
  • You and your patient make the decision
Patient: John Doe (ID: P12345)
Screened options (Condition: Alzheimer's disease)
Donanemab
Eligible
Effectiveness estimate:
57/100
Safety estimate:
48/100
Lecanemab
Eligible
Effectiveness estimate:
55/100
Safety estimate:
50/100
Donepezil
Eligible
Effectiveness estimate:
45/100
Safety estimate:
60/100
Rivastigmine
Eligible
Effectiveness estimate:
43/100
Safety estimate:
58/100

Recommend a Treatment, or Offer a Randomized Comparison

Recommend a screened treatment that your patient chooses with you. Or, if your patient agrees, enroll them in a centrally run randomized comparison, as the RECOVERY trial did.

  • Recommend any screened treatment, with written consent
  • Offer willing patients a randomized comparison
  • The trial assigns treatments at random; you never pick an arm
  • Compares treatments, doses or usual care, as the protocol sets
Patient: J. Doe
Recommend a treatmentScreened
Lecanemab (IV, every 2 weeks)
Decline on CDR-SB at 18 months27% slower
Brain swelling (ARIA-E)13%
Source: FDA label
Offer a randomized comparisonOptional
Alzheimer's comparison study

Compares screened treatments with each other or with usual care. The central trial assigns each patient at random.

Joins only with your patient's written consent.

Monitor Your Patients' Outcomes

Track how your patients are doing, report side effects in minutes, and see the same outcome categories the board publishes.

  • Outcome reports straight from routine medical records
  • Serious side effects reach the review board within five days
  • Good, bad and unclear results are all recorded
  • Compare your patients with every clinic's pooled results
Your Patients on Lecanemab
Outcome reports due this week3
Outcomes at 6 months (48 patients)
Improved21
No real change14
Worsened6
Stopped4
Lost to follow-up3
Recent side-effect reports

P12345: Mild ARIA, reported to the board

P67890: Headache (resolved)

For researchers

How Clinical Trials Should Work

Create a Trial

Upload protocols, pre/post-clinical data, and register your supply chain in one place.

  • Start from a protocol template
  • Submit the protocol to an independent review board
  • Keep the protocol, data and approvals in one record
Create New Trial
Upload Protocol

Get Liability Insurance

See liability insurance priced per participant before you enroll anyone.

  • Compare quotes side by side
  • Priced for your trial's risks
  • Cover starts before the first patient enrolls
Select Liability Insurance
SafeTrial Liability Insurance
Comprehensive coverage
Recommended
Per participant:$45
MedSecure Plus
Basic coverage
Per participant:$32

Set Parameters

Set what your study covers for each participant and what data it collects.

  • Cover participants' treatment and visit costs
  • Point patients to charity and maker assistance
  • Customizable data collection requirements
Trial Parameters
USD
CharityFree supply from maker
Blood GlucoseWeightActivityDiet

Manage Supply Chain & Orders

Ship treatment to participating clinics and track each order and shipment.

  • Stock at each clinic, with low-stock alerts
  • Patient orders filled through the clinic
  • Temperature logged in transit
  • An audit trail for every shipment
Supply Chain Dashboard
Inventory Status
In Stock
1,250 units
Allocated
840 units
Recent Orders
#ORD-2845
2 units • Processing
New
#ORD-2844
1 unit • Shipped
Delivered
Supply Chain Map
Interactive map view

See Results as They Come In

Outcomes from every clinic, pooled and compared across the trial's arms while it runs.

  • Results from the first patients, not only at the end
  • Whether patients took their doses
  • Who stopped, and who was lost to follow-up
  • De-identified data to export for regulators and journals
Trial results
Outcomes so far
New treatmentUsual care
Week 0Patients improvedWeek 12
Doses and check-ins
Doses on time
92%
Check-ins
4,265
Adverse Events
Total Reports
12
Requires Review
3

Why Care-Integrated Clinical Trials Matter

What the network would deliver for patients, clinicians and researchers

Easier for Patients

Taking part fits into ordinary care:

  • Join through your own doctor and take part from home, instead of traveling to a trial site
  • See your results next to others on the same treatment
  • Open to patients whom standard trials exclude

Lower Cost per Patient

Pragmatic trials show what is possible:

  • The RECOVERY trial cost about $500 per patient, compared with about $41,000 in the pivotal trials behind new FDA approvals
  • Data collection runs inside routine care
  • Automated analysis replaces manual site work

Sources: Manhattan Institute, 2023 (RECOVERY); Moore et al., JAMA Internal Medicine, 2018.

Better Data Quality

Designed for data that researchers can check and reuse:

  • Continuous data from apps and wearables, not only clinic visits
  • Every number shows where it came from
  • An open API for independent analysis

Faster Access to Treatments

Patients learn sooner what works:

  • Outcome data from the first patients, not only at the end of a multi-year trial
  • Rankings update as new evidence arrives

Partner with us

Clinics and doctors

Run a pilot site or advise us on the protocol.

Organizations building their own

The protocol and code are open source, so you can build your own version and publish results in the same open format.

Data partners

Apps, health record systems, registries and wearable makers would share outcome data through an open API, so their users' results count toward the rankings and labels.

Advisory board

We are recruiting clinicians, researchers, ethicists, lawyers and patient advocates to advise the initiative on the protocol, patient safety and the law.

Care-Integrated Clinical Trials Initiative